Sells a prescription drug combination for adults with recurrent KRAS-mutated low-grade serous ovarian cancer and develops cancer medicines for ovarian, pancreatic, lung and colorectal cancers.
10-K for FY2025, filed Mar 4, 2026We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed…View ↗
Our pipeline includes clinical-stage programs, preclinical research programs and externally partnered early-stage programs. Our focus is on…View ↗
For our clinical-stage pipeline programs, we are evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, for the…View ↗
AVMAPKI plus FAKZYNJA is only commercially available in the U.S. as an oral combination co-pack with the two prescription products, known…View ↗
$30.9M
10-K for FY2025, filed Mar 4, 2026
$30.9M ↗
Specialty pharmacies dispense the combination directly to patients, while specialty distributors resell it to healthcare entities that then resell it to patients.
10-K for FY2025, filed Mar 4, 2026Product Revenue, Net - The Company sells AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in…View ↗
No. It lost $209.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$74.7MView ↗
8-K, filed Aug 7, 2026
The Amendment amends the financing arrangement under the Note Purchase Agreement by establishing two separate series of senior secured…View ↗
8-K, filed Jun 23, 2026
On June 23, 2026, the Company also (i) announced preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375…View ↗
Growing. Revenue grew 15.1x in 4 years, from $2.1M in FY2021 to $30.9M in FY2025, about 97% a year.
Commercial product and customer sales
The earlier report described the company as developing cancer drug candidates, with no marketed product discussed. The latest report says it markets an approved drug combination in the United States.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 4, 2026
Broader drug pipeline
The earlier report focused on avutometinib and defactinib; the latest also describes a direct KRAS inhibitor as a clinical-stage program.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 4, 2026
Competes with Abbvie, AstraZeneca, Bristol Myers Squibb, Erasca, Genentech, Novartis, Pfizer, Astellas Pharma, Bayer, BeOne, Boehringer Ingelheim, Chugai, D3 Bio, Eli Lilly, GenFleet, Incyte, Jacobio, Jiangsu Hengrui Pharmaceuticals, Quanta Therapeutics, and Ranok Therapeutics
10-K for FY2025, filed Mar 4, 2026Several FDA-approved RAF and/or MEK inhibitors are commercially available; however, we are not aware of any products that are specifically…View ↗
Loading...